StockWatch
·
Biotechnology: Pharmaceutical Preparations
Quarterly ResultAug 13, 2026, 04:45 PM

Fortress Biotech 6M Net Income $109.9M; Cash $196.6M; Q2 Net Loss

AI Summary

Fortress Biotech reported a net income attributable to common stockholders of $105.89 million for the six months ended June 30, 2026, significantly up from $0.64 million in the prior year, largely driven by a $158.87 million gain from the sale of a priority review voucher. For the second quarter of 2026, the company posted a net loss of $2.48 million attributable to common stockholders, compared to a net income of $13.36 million in Q2 2025. Net revenue increased by 17.6% to $34.76 million for the six-month period. The company's cash and cash equivalents surged to $196.58 million, and it stated sufficient liquidity for at least 12 months.

Key Highlights

  • Net income attributable to Fortress for 6M 2026 was $109.91 million, up from $4.90 million in 6M 2025.
  • Net loss attributable to Fortress for Q2 2026 was $0.47 million, compared to net income of $15.49 million in Q2 2025.
  • Net revenue increased 17.6% to $34.76 million for the six months ended June 30, 2026.
  • Cash and cash equivalents rose to $196.58 million as of June 30, 2026, from $79.38 million at Dec 31, 2025.
  • Gain on sale of priority review voucher contributed $158.87 million to other income for 6M 2026.
  • Basic EPS for 6M 2026 was $3.34, up from $0.02 in 6M 2025.
  • Cyprium Therapeutics is eligible for up to $128 million in milestones and tiered royalties from Sentynl for ZYCUBO.
  • Company has sufficient cash to fund Parent Entity operations for at least 12 months.